Clinicopathological Profile of Carcinoma Breast and Its Association with Molecular Subtypes and Nodal Burden: A Cross-Sectional Observational Study at a Tertiary Care Hospital
DOI:
https://doi.org/10.48047/ybw6y456Keywords:
Breast carcinoma, molecular subtypes, HER2-enriched, Luminal, stage at diagnosisAbstract
Background: Breast cancer is the most prevalent female malignancy in India, and presentation at late stages and prevalence of triple-negative breast cancer (TNBC) are important clinical challenges. Clinical correlates of molecular subtype distribution and the burden of nodes in Indian tertiary care patients are not fully understood. Design, setting and participants: A cross sectional study was conducted in 180 women who were diagnosed with breast carcinoma in a tertiary care hospital over a period of 18 months. Age, stage, histological grade, clinical correlates, and molecular subtypes as determined by immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 were recorded. Results: The median age at diagnosis was 48 years (range 26-78); 41.1% were diagnosed with the condition before their menopause. Stage III at diagnosis in 38.3%; Stage IV in 12.2%. Molecular subtypes: Luminal A 32.2%, Luminal B 26.1%, HER2-enriched 17.8%, TNBC 23.9%. Of the patients, 58.3% had node-positive disease. Tumour size >2 cm, grade III, TNBC subtype and Ki-67 ≥ 20% were independent factors associated with nodal positivity (aOR 3.1, 2.4, and 1.7, respectively). Captions: A high proportion of the Indian breast cancer patients present with advanced stage disease. The proportion of high TNBC (23.9 %) and the high nodal positivity at diagnosis (58.3 %) in the study indicate the aggressive nature of Indian breast carcinoma. Population based screening via mammography and clinical breast examination should be given greatest emphasis.
Downloads
References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
National Cancer Registry Programme. Three year report of population based cancer registries 2012-2014. Bangalore: ICMR-NCDIR; 2016.
Mehrotra R, Yadav K. Breast cancer in India: present scenario and the challenges ahead. World J Clin Oncol. 2022;13(3):209-18.
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181-7.
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23.
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-522). Lancet. 2022;399(10338):1846-58.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Kumar S, Shaikh AJ, Khalid S. Spectrum of breast cancer management in the developing world: tertiary care experience. Asian Pac J Cancer Prev. 2012;13(8):3895-9.
Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-8
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
